ETON (Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued
ETON (Pharmaceuticals) trades at a blended P/E of 73.2, about 52% above its historical normal valuation, with a forward growth estimate of 96.0% and a PEG of 0.76.
Valuation flags
- Overvalued by 52%
Frequently asked questions
Is ETON overvalued?
At a blended P/E of 73.2 versus its historical normal P/E of 48.3, ETON trades about 52% above its typical valuation, with a PEG of 0.76 on 96.0% forward growth. tickerseer currently rates it significantly overvalued.
What is ETON's fair value and PEG?
ETON trades at a blended P/E of 73.2 against a historical normal P/E of 48.3, a PEG of 0.76, and a forward growth estimate of 96.0%.
Has tickerseer's rating of ETON changed?
tickerseer's rating has been significantly overvalued since 2026-08-07.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.